PBRM1: A Potential Negative Predictive Biomarker for immunotherapy in NSCLC
In our research, PBRM1 mutation was found to be a negative predictive biomarker of immunotherapy efficacy in NSCLC. Patients with PBRM1 mutation got less survival benefit from immunotherapy for NSCLC.